drugset / Trial / NCT07134335
UBT251 Injection Phase II Clinical Study (CKD)
RandomizedParallel-groupDouble-blindTreatment
Summary
This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
Timeline
- Start
- 2025-09-01
- Primary completion
- 2030-07-11
- Completion
- 2030-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UBT251 | Unknown | 2 mg | Subcutaneous |
| Subject | UBT251 | Unknown | 4 mg | Subcutaneous |
| Subject | UBT251 | Unknown | 6 mg | Subcutaneous |